Fig. 3: Gene expression of ECM biosynthetic and regulatory molecules in SUD and MDD.
From: Extracellular matrix abnormalities in the hippocampus of subjects with substance use disorder
A Gene expression of the ECM proteolytic molecule Mmp9 was significantly decreased in subjects with SUD compared to controls (p < 0.05), but no significant differences were detected in the other two diagnostic groups. B Analysis of covariance uncovered significantly decreased mRNA levels of cathepsin S in subjects with SUD (p < 0.03; adjusted for significant effects of cocaine in the toxicology report). Subjects with MDD had significantly increased expression of cathepsin S compared to controls (p < 0.03; adjusted for significant effects of alcohol history and ZT time of death). C Gene expression of the CSPG aggrecan was significantly increased in subjects with comorbid SUD and MDD (p < 0.03) but was unaffected in either condition separately. D Gene expression of the CSPG biosynthetic molecule Chsy1 was significantly increased in subjects with SUD (p < 0.05; adjusted for significant effects of tissue pH) and in subjects with comorbid SUD and MDD (p < 0.0001; adjusted for significant effects of tissue pH and duration of AUD), while patients with MDD did not meet significance in any direction. Error bars are mean ± SEM.
